Search

301 Result(s)
Sort by

View from Both Sides of the Table

View from Both Sides of the Table

Scott DeWire, US Head of BD&L shares experiences that have taught him first-hand the foundations of successful partnerships
Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim Access to Healthcare Strategy 2025

Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach.
Transforming Science Day Europe

Transforming Science Day Europe

Oct. 2, 2023: Join us in London, or virtually, to learn more about our patient-centric approach to innovation, advancing pipeline and partnering approach.
Our-position

Our-position

Potential access to selected medications for appropriate patients with serious, life-threatening diseases unable to participate in a clinical trial
Valerie Nock

Valerie Nock

My career challengeFunctional Areas at Boehringer Ingelheim
Fredrik Gruenenfelder

Fredrik Gruenenfelder

, Lead Risk Management Physician, talks about his career journey, from veterinarian to playing a key role in keeping patients safe.
BTD for GlyT1 in Schizophrenia

BTD for GlyT1 in Schizophrenia

Boehringer Ingelheim’s Investigational Treatment for Cognitive Impairment Associated with Schizophrenia receives FDA Breakthrough Therapy Designation
Spesolimab Phase II data

Spesolimab Phase II data

New data published in NEJM shows spesolimab improved signs & symptoms of GPP flares
RE-LY-trial-publication-10-year-anniversary

RE-LY-trial-publication-10-year-anniversary

Boehringer Ingelheim recognises the contribution made in the decade since the RE-LY® trial publication by patients, HCPs and researchers